darbepoetin alfa

Summary

Summary: A recombinant protein which stimulates ERYTHROPOIESIS used to treat ANEMIA.

Top Publications

  1. Minnerup J, Schäbitz W. Darbepoetin alfa and chronic kidney disease. N Engl J Med. 2010;362:653-4; author reply 655 pubmed
  2. Marsden P. Treatment of anemia in chronic kidney disease--strategies based on evidence. N Engl J Med. 2009;361:2089-90 pubmed publisher
  3. Winkelmayer W. Against TREATing all patients alike: lessons from an FDA Advisory Committee Meeting. J Am Soc Nephrol. 2011;22:1-2 pubmed publisher
  4. Mafodda A, Giuffrida D, Prestifilippo A, Azzarello D, Giannicola R, Mare M, et al. Oral sucrosomial iron versus intravenous iron in anemic cancer patients without iron deficiency receiving darbepoetin alfa: a pilot study. Support Care Cancer. 2017;25:2779-2786 pubmed publisher
    ..iron versus intravenous iron in increasing hemoglobin in anemic cancer patients receiving chemotherapy and darbepoetin alfa, as well as safety, need of transfusion, and quality of life (QoL)...
  5. Unger E, Thompson A, Blank M, Temple R. Erythropoiesis-stimulating agents--time for a reevaluation. N Engl J Med. 2010;362:189-92 pubmed publisher
  6. Forni V, Bianchi G, Ogna A, Salvadé I, Vuistiner P, Burnier M, et al. Reticulocyte dynamic and hemoglobin variability in hemodialysis patients treated with Darbepoetin alfa and C.E.R.A.: a randomized controlled trial. BMC Nephrol. 2013;14:157 pubmed publisher
    ..Four subcutaneous treatment strategies (C.E.R.A. every 4 weeks Q4W and every 2 weeks Q2W, Darbepoetin alfa Q4W and Q2W) were compared with each other...
  7. Steensma D, Sasu B, Sloan J, Tomita D, Loprinzi C. Serum hepcidin levels predict response to intravenous iron and darbepoetin in chemotherapy-associated anemia. Blood. 2015;125:3669-71 pubmed publisher
  8. Saglimbene V, Palmer S, Ruospo M, Natale P, Craig J, Strippoli G. Continuous erythropoiesis receptor activator (CERA) for the anaemia of chronic kidney disease. Cochrane Database Syst Rev. 2017;8:CD009904 pubmed publisher
    ..To assess benefits and harms of CERA compared with other epoetins (darbepoetin alfa and epoetin alfa or beta) or placebo/no treatment or CERA with differing strategy of administration for ..
  9. Bohlius J, Schmidlin K, Brillant C, Schwarzer G, Trelle S, Seidenfeld J, et al. Erythropoietin or Darbepoetin for patients with cancer--meta-analysis based on individual patient data. Cochrane Database Syst Rev. 2009;:CD007303 pubmed publisher
    ..42). ESA treatment in cancer patients increased on study mortality and worsened overall survival. For patients undergoing chemotherapy the increase was less pronounced, but an adverse effect could not be excluded. ..

More Information

Publications14

  1. Varlet Marie E, Audran M, Ashenden M, Sicart M, Piquemal D. Modification of gene expression: help to detect doping with erythropoiesis-stimulating agents. Am J Hematol. 2009;84:755-9 pubmed publisher
  2. Goldsmith D, Covic A. Time to Reconsider Evidence for Anaemia Treatment (TREAT) = Essential Safety Arguments (ESA). Nephrol Dial Transplant. 2010;25:1734-7 pubmed publisher
  3. Paliga A, Shahbazi N, Gonsalves C, Bormanis J, Padmore R. Trilineage myelodysplasia and hemophagocytosis associated with systemic lupus erythematosus. Am J Hematol. 2012;87:529-30 pubmed publisher
  4. Winkelmayer W, Mitani A, Goldstein B, Brookhart M, Chertow G. Trends in anemia care in older patients approaching end-stage renal disease in the United States (1995-2010). JAMA Intern Med. 2014;174:699-707 pubmed
    ..9 g/dL in 2010. Between 1995 and 2010, older adults approaching ESRD were increasingly more likely to be treated with ESAs and to receive intravenous iron supplementation, but also more likely to receive blood transfusions. ..
  5. Platzbecker U, Symeonidis A, Oliva E, Goede J, Delforge M, Mayer J, et al. A phase 3 randomized placebo-controlled trial of darbepoetin alfa in patients with anemia and lower-risk myelodysplastic syndromes. Leukemia. 2017;31:1944-1950 pubmed publisher
    The use of darbepoetin alfa to treat anemia in patients with lower-risk myelodysplastic syndromes (MDS) was evaluated in a phase 3 trial...